CAS 1111556-37-6

1-N-(1-propyl-1H-1,3-benzodiazol-2-yl)benzene-1,3-dicarboxamide

CAS : 1111556-37-6

Formule : C₁₈H₁₈N₄O₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 322.3611

Ref: IN-DA01DUZB

Takinib

CAS : 1111556-37-6

Takinib

Degré de pureté : ≥98%

Masse moléculaire : 322.36g/mol

Ref: 54-BUP06020

Takinib

CAS : 1111556-37-6

Takinib (EDHS-206) is a specific and effective TAK1 inhibitor(IC50= 9.5 nM).

Formule : C₁₈H₁₈N₄O₂

Degré de pureté : 98.29% - 99.35%

Couleur et forme : Solid

Masse moléculaire : 322.36

Ref: TM-T4264

Takinib

Produit contrôlé

CAS : 1111556-37-6

Takinib is a small molecule that is being developed as a treatment for inflammatory bowel disease (IBD). Takinib inhibits the production of pro-inflammatory factors, including cytokines and chemokines. It also reduces the proliferation of cancer cells. Takinib has been shown to be effective in inhibiting cisplatin-induced nephrotoxicity in vivo. It has also been shown to inhibit angiogenesis by suppressing the expression of vascular endothelial growth factor (VEGF) and to induce apoptosis in activated T cells. The molecule also inhibits the expression of molecules such as tumor necrosis factor alpha (TNFα), interleukin 6 (IL6), and monocyte chemoattractant protein 1 (MCP1). The drug's effectiveness against IBD has been demonstrated in a number of clinical trials. The drug has an effective dose of 10mg/kg/day, which is administered orally for up to 12 weeks.

Formule : C₁₈H₁₈N₄O₂

Degré de pureté : Min. 95%

Masse moléculaire : 322.36 g/mol

Ref: 3D-LUB55637